Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Vertex Selects VX-445 For CF Triple Therapy Due To Safety/Tolerability

May 30 2019

• By Joseph Haas

Cystic Fibrosis — Vertex develops and markets therapies addressing the underlying cause of CF

Related Content

Vertex's CF Three-Drug Combo Excels In Phase III, But Filing Depends On Second Regimen's Results

Nov 29 2018

Vertex Set To Dominate Cystic Fibrosis Market For The Next Decade

Sep 24 2018

Cystic Fibrosis Triplet Could Unblock EU Reimbursement Impasse

May 01 2019

Vertex Stuck Between A Good Place And A Better Place

Mar 06 2019

Proteostasis Puts Best Face On Unspectacular CF Combo Data

Mar 25 2019

Related Companies

Vertex Pharmaceuticals Incorporated

Proteostasis Therapeutics, Inc.

AbbVie Inc.

Galapagos NV

Additional Topics

Clinical Trials Research & Development Respiratory BioPharmaceutical

More from Respiratory

More from Therapeutic Category

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.